Home 2017-09-01T14:30:22+00:00


Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) is a not-for-profit organisation, founded in 2000 with the mission to perform research and provide scientific, economic and regulatory consultancy for innovation in the health sector at European level. The main fields of interest are life sciences and biotechnologies, drug development for small populations (pediatric and rare diseases), research management andmethodology, monitoring, statistics, regulatory, ethics and pharmacovigilance.

Who we are


Development and application of innovative methodologies in clinical trials for small populations, management of disease registries, execution of studies in the pharmacological field. Find out more.
Development and supervision of dossiers and documentation regarding national and European authorisation procedures for medicinal products. Find out more.
Development and management of all clinical trial phases, which are performed by the Consortium both as a Sponsor and as a Contract Research Organisation (CRO). Find out more.
Educational activities addressed to public bodies, research institutes and private companies, also within CME programmes. Find out more.
Management and participation to medical research projects and consortiums at national and international level. Find out more.
Design and management of registries and drug databases. Find out more.
Research networks aimed to facilitate transfer of know-how and to promote national and international research as well as scientific excellence. Find out more.
CVBF Brochure

On-going Projects

Slide background
Slide background
Slide background
Slide backgroundSlide thumbnail
Slide background
Closed logo
logo innermed
Slide background

Latest News

1010, 2017

CVBF will be involved in 2 projects recently funded within the AIFA 2016 Call

The Italian Medicines Agency (AIFA) announced the conclusion of the double-stage selection process for the AIFA 2016 call. Among the 343 clinical protocols submitted and considered eligible, 40 projects have been approved for a total value [...]

410, 2017

Revised guideline on first-in-human clinical trials

On 25th, July 2017, the European Medicines Agency (EMA) published a revision of the guidance on first-in-human clinical trials, that will come into effect on February 1st, 2018. […]